, Tracking Stock Market Picks
Enter Symbol:
Optimer Pharmaceuticals, Inc. (OPTR) [hlAlert]

up 16.97 %

Optimer Pharmaceuticals, Inc. (OPTR) rated Underperform by BofA/Merrill

Posted on: Tuesday,  Sep 18, 2012  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Underperform Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) on 09/18/2012, when the stock price was $14.95. Since
then, Optimer Pharmaceuticals, Inc. has lost 14.52% as of 10/23/2013's recent price of $12.78.
If you would have followed this BofA/Merrill's recommendation on OPTR, you would have gained 16.97% of your investment in 400 days.

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. The Company?s development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. It has two late-stage anti-infective product candidates: fidaxomicin (formerly OPT-80) and prulifloxacin. Fidaxomicin, the Company?s lead product candidate, is an antibiotic in its second Phase III registration trial for the treatment of Clostridium difficile-infections (CDI), the common nosocomial, or hospital acquired diarrhea. Prulifloxacin is a prodrug in the fluoroquinolone class of antibiotics. The Company is developing additional product candidates using its technology, including its Optimer One-Pot Synthesis (OPopS) drug discovery platform. OPopS is a computer-aided technology that enables the rapid and low-cost synthesis of an array of carbohydrate-based compounds.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/18/2012 8:25 AM Sell
as of 12/31/2012
1 Week up  1.63 %
1 Month up  11.01 %
3 Months up  35.90 %
1 YTD up  39.46 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy